Constipation • Intestinal transit • Oxalate degradation • Reduction of intestinal inflammation • Potential reduction of kidney stones incidence
- > Bifidobacterium longum – BL03 (DSM 16603)
Bifidobacterium longum – BL03 (DSM 16603)
Discover characteristics, functionalities and scientific support of Bifidobacterium longum – BL03 (DSM 16603).
Thearapeutical Area(s): Gastrointestinal tract, Urogenital system
Age/Gender: Adults
Scientific reference(s)
Del Piano M. et al. The use of probiotics in the treatment of constipation in the elderly (BL03, LP01, BS01, LR05, BA02 and BR03 seperately). CIBUS, 2005; 1(1):23-30.
Del Piano M. et al. In Vitro Sensitivity of Probiotics to Human Pancreatic Juice (LA02, LPC00, LP01, LR04, BR03, BL03 and BA02). J Clin Gastroenterol. Vol 42, Suppl. 3, Part 2, Sept. 2008.
Rossi M. et al. fermentation of fructooligosaccharides and inulin by Bifidobacteria: a comparative study of pure and fecal cultures (BA02). Applied and Environmental Microbiology, 2005;71(10):6150-6158.
Mogna L. et al. Screening of different probiotic strains for their in vitro ability to metabolise oxalates: any prospective use in humans? (LPC09, LA02, LP01, LRE02, BR03, BL03) J Clin Gastroenterol. 2014; 48 Suppl:S91-95.
